Literature DB >> 4323439

Hypothalamic-pituitary-adrenal function in patients treated with long-term depot tetracosactrin.

W J Irvine, D R Cullen, S A Khan, J G Ratcliffe.   

Abstract

Four patients treated with depot tetracosactrin for 10 to 18 months maintained normal hypothalamic-pituitary-adrenal function assessed by the nyctohemeral variation of plasma corticosteroids and by the responses of plasma corticosteroids to insulin-induced hypoglycaemia, lysine-vasopressin, and depot tetracosactrin. The pituitary component of the response was analysed by measuring plasma immunoreactive ACTH levels. Three patients showed a nyctohemeral ACTH rhythm and normal ACTH responses to insulin-induced hypoglycaemia. Consistently undetectable morning plasma ACTH levels were found in the fourth patient, who also showed an unusually delayed rise in both ACTH and corticosteroid levels in response to insulin-induced hypoglycaemia, though the peak values attained were normal.The lack of suppression of hypothalamic-pituitary-adrenal function together with the good clinical response in these four patients suggests that treatment with depot tetracosactrin should be considered when long-term corticosteroid therapy is required.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4323439      PMCID: PMC1795405          DOI: 10.1136/bmj.1.5750.630

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  12 in total

1.  NATURAL HISTORY OF PITUITARY-ADRENAL RECOVERY FOLLOWING LONG-TERM SUPPRESSION WITH CORTICOSTEROIDS.

Authors:  A L GRABER; R L NEY; W E NICHOLSON; D P ISLAND; G W LIDDLE
Journal:  J Clin Endocrinol Metab       Date:  1965-01       Impact factor: 5.958

2.  Immunoreactive corticotrophin levels in adrenocortical insufficiency.

Authors:  G M Besser; D R Cullen; W J Irvine; J G Ratcliffe; J Landon
Journal:  Br Med J       Date:  1971-02-13

3.  Effect of corticotrophin therapy on pituitary-adrenal function.

Authors:  M E Carter; V H James
Journal:  Ann Rheum Dis       Date:  1970-01       Impact factor: 19.103

4.  Intermittent therapy with corticotrophin.

Authors:  J K Nelson; J S Mackay; B Sheridan; J A Weaver
Journal:  Lancet       Date:  1966-07-09       Impact factor: 79.321

5.  Antibodies to corticotrophin and their relation to adrenal function in children receiving corticotrophin therapy.

Authors:  J Landon; M Friedman; F C Greenwood
Journal:  Lancet       Date:  1967-03-25       Impact factor: 79.321

6.  Hypothalamo-pituitary-adrenal function in asthmatic patients receiving long-term corticosteroid therapy.

Authors:  D N Malone; I W Grant; I W Percy-Robb
Journal:  Lancet       Date:  1970-10-10       Impact factor: 79.321

7.  Hypothalamo-pituitary-adrenal function in patients on long-term adrenocorticotrophin therapy.

Authors:  P A Bacon; J R Daly; A B Myles; O Savage
Journal:  Ann Rheum Dis       Date:  1968-01       Impact factor: 19.103

8.  Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis.

Authors:  J R Daly; A B Myles; P A Bacon; C G Beardwell; O Savage
Journal:  Ann Rheum Dis       Date:  1967-01       Impact factor: 19.103

9.  Tests of hypothalamic-pituitary-adrenal function in man.

Authors:  H S Jacobs; J D Nabarro
Journal:  Q J Med       Date:  1969-10

10.  The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects.

Authors:  F S Plumpton; G M Besser
Journal:  Br J Surg       Date:  1969-03       Impact factor: 6.939

View more
  2 in total

Review 1.  Antiasthmatic drugs. II. Therapeutic aspects.

Authors:  A S Rebuck
Journal:  Drugs       Date:  1974       Impact factor: 9.546

2.  Hormonal effects of synthetic ACTH analogues.

Authors:  A D Toft; W J Irvine
Journal:  Proc R Soc Med       Date:  1974-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.